Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, discusses Gilead’s groundbreaking HIV prevention innovation — a twice-yearly injection with 99.9% efficacy during this week’s episode of CNBC Changemakers and Power Players.
